In November of 2014, Arizona voters approved the so-called Right to Try ballot initiative. The goal is to give terminally-ill patients the chance to try experimental drugs that hadn’t been given the go-ahead by the Food and Drug Administration.
Some opponents of the measure said it wasn’t needed because of a federal program called “Compassionate Use.” But in a new investigative report called Dead on Arrival, Mark Flatten of the Goldwater Institute found that “Compassionate Use” is a very limited option.
The Goldwater Institute was strongly behind the efforts to pass Right to Try in Arizona and other states.
